R. G. Cooper

1.1k total citations
10 papers, 744 citations indexed

About

R. G. Cooper is a scholar working on Oncology, Pharmacology and Pharmacology. According to data from OpenAlex, R. G. Cooper has authored 10 papers receiving a total of 744 indexed citations (citations by other indexed papers that have themselves been cited), including 4 papers in Oncology, 3 papers in Pharmacology and 3 papers in Pharmacology. Recurrent topics in R. G. Cooper's work include Drug Transport and Resistance Mechanisms (3 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). R. G. Cooper is often cited by papers focused on Drug Transport and Resistance Mechanisms (3 papers), Antibiotics Pharmacokinetics and Efficacy (3 papers) and Pharmacogenetics and Drug Metabolism (3 papers). R. G. Cooper collaborates with scholars based in United Kingdom, Saudi Arabia and United States. R. G. Cooper's co-authors include A. Hayes, C. T. Dollery, James W. Paterson, M. E. Conolly, David A. Evans, Alexander Fraser, Allan H. Price, Daniel F. Carr, Ana Alfirevic and Anke H. Maitland‐van der Zee and has published in prestigious journals such as Journal of Pharmacology and Experimental Therapeutics, Clinical Pharmacology & Therapeutics and Journal of Medical Genetics.

In The Last Decade

R. G. Cooper

10 papers receiving 666 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
R. G. Cooper United Kingdom	8	182	172	141	124	124	10	744
Alan Rubin United States	18	241 1.3×	213 1.2×	350 2.5×	109 0.9×	74 0.6×	44	1.1k
D R Abernethy United States	16	108 0.6×	278 1.6×	204 1.4×	143 1.2×	48 0.4×	31	981
L. M. Fuccella Italy	15	128 0.7×	64 0.4×	176 1.2×	108 0.9×	61 0.5×	24	742
P J Pentikäinen Finland	14	77 0.4×	129 0.8×	73 0.5×	90 0.7×	41 0.3×	32	790
Ola Rönn Sweden	13	94 0.5×	142 0.8×	119 0.8×	60 0.5×	83 0.7×	25	545
Barry R. Walker United States	17	83 0.5×	103 0.6×	184 1.3×	93 0.8×	45 0.4×	42	723
N. Baber United Kingdom	18	164 0.9×	93 0.5×	166 1.2×	65 0.5×	92 0.7×	34	1.1k
Emil R. Smith United States	16	113 0.6×	79 0.5×	133 0.9×	211 1.7×	41 0.3×	45	840
Edward J. Randinitis United States	18	164 0.9×	232 1.3×	194 1.4×	231 1.9×	75 0.6×	43	1.3k
Eva Steiness Denmark	20	102 0.6×	108 0.6×	166 1.2×	300 2.4×	86 0.7×	75	1.3k

Countries citing papers authored by R. G. Cooper

Since Specialization

Citations

This map shows the geographic impact of R. G. Cooper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by R. G. Cooper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites R. G. Cooper more than expected).

Fields of papers citing papers by R. G. Cooper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by R. G. Cooper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by R. G. Cooper. The network helps show where R. G. Cooper may publish in the future.

Co-authorship network of co-authors of R. G. Cooper

This figure shows the co-authorship network connecting the top 25 collaborators of R. G. Cooper. A scholar is included among the top collaborators of R. G. Cooper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with R. G. Cooper. R. G. Cooper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

10 of 10 papers shown

Alfirevic, Ana, D. Neely, Jane Armitage, et al.. (2014). Phenotype Standardization for Statin-Induced Myotoxicity. Clinical Pharmacology & Therapeutics. 96(4). 470–476. 150 indexed citations

Fraser, Alexander, et al.. (1999). Predicting 'normal' grip strength for rheumatoid arthritis patients. Lara D. Veeken. 38(6). 521–528. 93 indexed citations

Cooper, R. G., S A Jenkins, David A. Evans, & Allan H. Price. (1988). The enterohepatic circulation of perhexiline metabolites in the male Wistar rat. Xenobiotica. 18(4). 389–396. 1 indexed citations

Cooper, R. G., David A. Evans, & Allan H. Price. (1987). Studies on the metabolism of perhexiline in man. European Journal of Clinical Pharmacology. 32(6). 569–576. 26 indexed citations

Cooper, R. G., G. S. Harper, Allan H. Price, David A. Evans, & David J. Lockhart. (1986). Simultaneous determination of perhexiline and its monohydroxy metabolites in biological fluids by gas chromatography—electron-capture detection. Journal of Chromatography B Biomedical Sciences and Applications. 381(2). 305–314. 10 indexed citations

Cooper, R. G., et al.. (1984). Polymorphic hydroxylation of perhexiline maleate in man.. Journal of Medical Genetics. 21(1). 27–33. 59 indexed citations

Bateman, D. Nicholas, R. G. Cooper, Geoffrey Gibson, E. Peel, & I Wandless. (1981). Levodopa dosage and ventilatory function in Parkinson's disease.. BMJ. 283(6285). 190–191. 10 indexed citations

Hayes, A. & R. G. Cooper. (1971). STUDIES ON THE ABSORPTION, DISTRIBUTION AND EXCRETION OF PROPRANOLOL IN RAT, DOG AND MONKEY. Journal of Pharmacology and Experimental Therapeutics. 176(2). 302–311. 155 indexed citations

Paterson, James W., M. E. Conolly, C. T. Dollery, A. Hayes, & R. G. Cooper. (1970). The pharmacodynamics and metabolism of propranolol in man. European Journal of Clinical Pharmacology. 2(3). 127–133. 234 indexed citations

10.

Conolly, M. E., James W. Paterson, C. T. Dollery, A. Hayes, & R. G. Cooper. (1970). Pharmacological and Metabolic Studies with Propranolol in Man. Clinical Science. 38(2). 10P–10P. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact